PMID- 26214636
OWN - NLM
STAT- MEDLINE
DCOM- 20150825
LR  - 20161125
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 20
IP  - 3
DP  - 2015 May-Jun
TI  - BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit 
      from R-CHOP therapy irrespective of germinal and non germinal center B cell like 
      subtypes.
PG  - 820-8
AB  - PURPOSE: Despite major advances in the treatment of diffuse large B cell lymphoma 
      (DLBCL), approximately one third of the patients progress or die, suggesting the 
      existence of additional oncogenic events. The purpose of this study was to 
      evaluate the prognostic value of the "Hans classifier", and BCL2 and MYC protein 
      expression and gene alterations in DLBCL patients treated with CHOP or R-CHOP 
      chemotherapy over a 5-year period. Furthermore, we tried to correlate these 
      parameters with the International Prognostic Index (IPI). METHODS: The 
      immunohistochemical (IHC) expression of CD10, BCL6, MUM1 and BCL2 on 
      paraffin-embedded formalin-fixed tumor samples from 103 centroblastic DLBCLs was 
      analyzed. IHC expression of MYC and fluorescence in situ hybridization (FISH) for 
      MYC and BCL2 gene alterations was performed on 67 samples using the tissue 
      microarray (TMA) method. RESULTS: The Hans algorithm was not predictive of 
      survival in both therapy groups. No significant difference in BCL2 and MYC 
      alterations or MYC protein expression in relation to complete response (CR), 
      event-free survival (EFS) and overall survival (OS) was observed in our study. 
      High IPI correlated significantly with poor outcome and it was identified as 
      independent prognostic factor for OS and EFS (both p=0.000). The 5-year OS was 
      61% in the R-CHOP compared to 38% in the CHOP group (p=0.007). Rituximab 
      significantly improved the OS in the BCL2 positive (60 vs 29%, p=0.008), and the 
      BCL6 negative (73 vs 25%, p=0.001) cases. CONCLUSION: IPI is an independent 
      prognosticator for DL-BCL patients and the addition of rituximab significantly 
      improved survival. Furthermore, patients with BCL2+ and BCL6-DLBCL benefited from 
      R-CHOP.
FAU - Jovanovic, Maja Perunicic
AU  - Jovanovic MP
AD  - Department of Pathology, Clinical Center of Serbia, Belgrade, Serbia.
FAU - Mihaljevic, Biljana
AU  - Mihaljevic B
FAU - Jakovic, Ljubomir
AU  - Jakovic L
FAU - Martinovic, Vesna Cemerikic
AU  - Martinovic VC
FAU - Fekete, Marija Dencic
AU  - Fekete MD
FAU - Andjelic, Bosko
AU  - Andjelic B
FAU - Antic, Darko
AU  - Antic D
FAU - Bogdanovic, Andrija
AU  - Bogdanovic A
FAU - Boricic, Novica
AU  - Boricic N
FAU - Terzic, Tatjana
AU  - Terzic T
FAU - Jelicic, Jelena
AU  - Jelicic J
FAU - Milenkovic, Sanja
AU  - Milenkovic S
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Antibodies, Monoclonal, Murine-Derived)
RN  - 0 (BCL2 protein, human)
RN  - 0 (BCL6 protein, human)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (MYC protein, human)
RN  - 0 (Proto-Oncogene Proteins c-bcl-2)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (R-CHOP protocol)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Algorithms
MH  - Antibodies, Monoclonal, Murine-Derived/administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - B-Lymphocytes/chemistry/*drug effects/immunology
MH  - Biomarkers, Tumor/*analysis/genetics
MH  - Cyclophosphamide/administration & dosage
MH  - DNA-Binding Proteins/*analysis
MH  - Decision Support Techniques
MH  - Disease-Free Survival
MH  - Doxorubicin/administration & dosage
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Lymphoma, Large B-Cell, Diffuse/chemistry/*drug 
      therapy/genetics/immunology/mortality/pathology
MH  - Predictive Value of Tests
MH  - Prednisone/administration & dosage
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Proteins c-bcl-2/*analysis/genetics
MH  - Proto-Oncogene Proteins c-bcl-6
MH  - Proto-Oncogene Proteins c-myc/genetics
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Rituximab
MH  - Time Factors
MH  - Tissue Array Analysis
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage
EDAT- 2015/07/28 06:00
MHDA- 2015/08/26 06:00
CRDT- 2015/07/28 06:00
PHST- 2015/07/28 06:00 [entrez]
PHST- 2015/07/28 06:00 [pubmed]
PHST- 2015/08/26 06:00 [medline]
PST - ppublish
SO  - J BUON. 2015 May-Jun;20(3):820-8.